Get the Stockscreener App
67.00
5.78%
-4.11
Pre-market:
67.11
0.11
+0.16%
Disc Medicine Inc stock is traded at $67.00, with a volume of 454.52K.
It is down -5.78% in the last 24 hours and down -0.87% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$71.11
Open:
$70.51
24h Volume:
454.52K
Relative Volume:
0.93
Market Cap:
$2.56B
Revenue:
-
Net Income/Loss:
$-212.18M
P/E Ratio:
-11.19
EPS:
-5.9897
Net Cash Flow:
$-181.33M
1W Performance:
-3.69%
1M Performance:
-0.87%
6M Performance:
-28.16%
1Y Performance:
+39.55%
1-Day Range:
$66.74
$71.81
1-Week Range:
$66.74
$72.83
52-Week Range:
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
67.00 | 2.72B | 0 | -212.18M | -181.33M | -5.9897 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Fierce Biotech Layoff Tracker 2026: Fulcrum cuts 85% of staff; Novartis trims research team - Fierce Biotech
Liquidity Mapping Around (IRON) Price Events - Stock Traders Daily
Diamond Blackfan Anemia Market Unlocking New Revenue - openPR.com
Medpace Deadline: MEDP Investors with Losses in Excess of $100K Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit - PR Newswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - PR Newswire
BRTX: Advancing late-stage cell therapies for spine, metabolic, and aesthetic markets with strong IP - TradingView
IRON: Bitopertin advances toward pivotal data and regulatory milestones, targeting broad anemia indications - TradingView
Program provides early access to experimental EPP treatment - Porphyria News
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $111 - Moomoo
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $100 to $118 - Moomoo
Stifel reiterates Disc Medicine stock rating on anemia trial data By Investing.com - Investing.com Australia
Stifel reiterates Disc Medicine stock rating on anemia trial data - Investing.com
Disc Medicine (IRON) Reports Promising Results from RALLY-MF Pha - GuruFocus
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Experimental anemia drug cuts transfusions in myelofibrosis trial - Stock Titan
How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients - Yahoo Finance
Disc Medicine Launches Expanded Access Program for Bitopertin for Epp Patients - marketscreener.com
Disc Medicine launches expanded access program for bitopertin By Investing.com - Investing.com South Africa
Disc Medicine launches expanded access program for bitopertin - Investing.com
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients - The Manila Times
Disc program offers EPP patients bitopertin before FDA decision - Stock Titan
IRON Technical Analysis & Stock Price Forecast - Intellectia AI
STLA Deadline: STLA Investors with Losses in Excess of $100K Have Opportunity to Lead Stellantis N.V. Securities Fraud Lawsuit - PR Newswire
IRON Should I Buy - Intellectia AI
Seven Grand Managers LLC Buys Shares of 35,000 Disc Medicine, Inc. $IRON - MarketBeat
Press releases provided by CNW - Techaeris
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data - inkl
Disc Medicine eyes mid-2026 bitopertin approval as EPP trial demand surges - MSN
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges - MarketBeat
Class action lawsuit launched over Disc Medicine's FDA drug rejection causing 22% stock drop - Pluang
Why (IRON) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Disc Medicine faces class action after FDA rejects drug application, stock drops 22%. - Pluang
IRON News | DISC MEDICINE INC (NASDAQ:IRON) - ChartMill
Eagle Health Investments LP Purchases Shares of 27,100 Disc Medicine, Inc. $IRON - MarketBeat
IRON: APOLLO study enrollment exceeded targets, signaling high demand and unmet need for EPP therapies - TradingView
DNB Asset Management AS Raises Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
First Light Asset Management, LLC's Disc Medicine Inc(IRON) Holding History - GuruFocus
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inqui - GuruFocus
Disc Medicine faces class action after FDA rejects drug application, stock drops 22% - Pluang
UBS Group AG Reduces Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative? - simplywall.st
Disc Medicine, Inc.Common Stock (NQ: IRON - FinancialContent
IRON Maintained by Morgan Stanley -- Price Target Raised to $80. - GuruFocus
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON) - The Globe and Mail
Morgan Stanley Raises Price Target on Disc Medicine to $80 From $75, Keeps Overweight Rating - marketscreener.com
Morgan Stanley Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $80 - Moomoo
Understanding Momentum Shifts in (IRON) - Stock Traders Daily
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Disc Medicine Inc Stock (IRON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Franchi Jean M. | Chief Financial Officer |
Apr 14 '26 |
Sale |
69.24 |
6,257 |
433,234 |
64,333 |
| Franchi Jean M. | Chief Financial Officer |
Apr 13 '26 |
Sale |
69.00 |
400 |
27,600 |
70,590 |
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):